NSCLC ADENOCARCINOMA
Clinical trials for NSCLC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NSCLC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for NSCLC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug MGC028 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colon cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or stop them from g…
Matched conditions: NSCLC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 26, 2026 11:21 UTC
-
New drug targets Hard-to-Treat cancers with rare gene deletion
Disease control Recruiting nowThis early-stage study tests a new drug called IDE892, alone or with other medicines, in people with advanced solid tumors that lack a gene called MTAP. The goal is to see if the drug is safe and can shrink tumors. About 260 adults with certain cancers (like lung, stomach, bladde…
Matched conditions: NSCLC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated May 22, 2026 13:53 UTC